Fig. 5: Effect of the PGS on the primary trial outcomes among individuals included in trial emulations and in the full study population. | Nature Genetics

Fig. 5: Effect of the PGS on the primary trial outcomes among individuals included in trial emulations and in the full study population.

From: Incorporating genetic data improves target trial emulations and informs the use of polygenic scores in randomized controlled trial design

Fig. 5

a, Effect of the outcome PGS on the primary outcome within each 1:1 nearest-neighbor PS-matched trial cohort using Cox regression and adjusting for the treatment, as well as within the full FinnGen population. HRs per one s.d. increase in genetic liability, and their 95% CIs are illustrated in the central forest plot. Points represent estimated HRs; horizontal lines denote 95% CIs. The vertical continuous line indicates the null value (HR = 1). b, Sample size reduction of the emulated Empareg and Tecos trials after enriching the trial cohorts with individuals at the top 25% genetic risk for CHD (top 25% CHD PGS). Sys. embol., systemic embolism.

Source data

Back to article page